Available in the shop
- Retatrutide 5 mg — $157.50
- Retatrutide 10 mg — $231.00
- Retatrutide 15 mg — $273.00
- Retatrutide 20 mg — $378.00
- Retatrutide 30 mg — $483.00
- Retatrutide 40 mg — $567.00
Sold for in vitro laboratory research only — not for human or animal consumption. ≥99% purity specification.
Identification
| Field of research | Weight research |
|---|---|
| PubChem name | Triple G |
| Formula | C221H342N46O68 |
| Molecular weight | 4731 g/mol |
| Also known as | orb1981169, EX-A7826E, GTPL13769, T76279 |
| PubChem | CID 171390338 |
Summary
Retatrutide is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company.
From Wikipedia, available under CC BY-SA 4.0. Short description from Wikidata (CC0).
Published research
Titles are shown as published. Listing a paper is not an endorsement of its findings, and many papers on research peptides are laboratory or animal studies: the type of study is shown when PubMed records it.
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trialRandomized Controlled TrialClinical Trial, Phase IIIMulticenter StudyResearch Support, Non-U.S. Gov'tBajaj HS, Welch M, Shah P et al. · Lancet, 2026 · PMID 42250575 · DOI
- Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled TrialsSystematic ReviewMoiz A, Filion KB, Toutounchi H et al. · Ann Intern Med, 2025 · PMID 39761578 · DOI
- Novel GLP-1-based Medications for Type 2 Diabetes and ObesityReviewSon JW, le Roux CW, Blüher M et al. · Endocr Rev, 2026 · PMID 41054801 · DOI
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 TrialRandomized Controlled TrialClinical Trial, Phase IIJastreboff AM, Kaplan LM, Frías JP et al. · N Engl J Med, 2023 · PMID 37366315 · DOI
- Retatrutide-A Game Changer in Obesity PharmacotherapyReviewKatsi V, Koutsopoulos G, Fragoulis C et al. · Biomolecules, 2025 · PMID 40563436 · DOI
- Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and ObesityReviewResearch Support, Non-U.S. Gov'tDrucker DJ · Diabetes Care, 2024 · PMID 38843460 · DOI
- Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db miceComparative StudyMa J, Hu X, Zhang W et al. · Endocrine, 2025 · PMID 39212900 · DOI
- Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysisComparative StudyNetwork Meta-AnalysisSystematic ReviewLiu S, Hu J, Zhao C et al. · Front Endocrinol (Lausanne), 2025 · PMID 39968298 · DOI
Top 8 of 193 results, by relevance. See all on PubMed.
Search query "Retatrutide"[Title/Abstract]
Data provenance
| Data | Source | Record |
|---|---|---|
| Chemical identity and structure | PubChem | CID 171390338 |
| Published literature | PubMed | Search on PubMed |
| Summary sentence | Wikipedia | Retatrutide |
Data retrieved 2026-10-08. See About for the sources. How the data is collected and checked: Methods.